Artivion, Inc. (NYSE:AORT) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP cut its stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 4.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,472,714 shares of the company's stock after selling 68,849 shares during the period. Dimensional Fund Advisors LP owned 3.51% of Artivion worth $42,105,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in AORT. Wasatch Advisors LP grew its holdings in shares of Artivion by 27.7% during the fourth quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company's stock worth $29,791,000 after buying an additional 226,160 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Artivion during the third quarter worth about $5,798,000. First Trust Advisors LP purchased a new stake in shares of Artivion during the 4th quarter worth about $4,771,000. Next Century Growth Investors LLC grew its stake in Artivion by 29.7% during the 4th quarter. Next Century Growth Investors LLC now owns 492,653 shares of the company's stock valued at $14,085,000 after purchasing an additional 112,918 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Artivion by 394.9% in the third quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company's stock worth $2,606,000 after buying an additional 78,120 shares during the period. 86.37% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Artivion

In related news, CEO James P. Mackin sold 42,156 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the sale, the chief executive officer now owns 663,882 shares in the company, valued at approximately $18,130,617.42. This represents a 5.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider John E. Davis sold 15,100 shares of Artivion stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total value of $356,511.00. Following the sale, the insider now directly owns 208,778 shares of the company's stock, valued at $4,929,248.58. This represents a 6.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,799 shares of company stock worth $2,356,223 over the last 90 days. Insiders own 7.60% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Stifel Nicolaus cut their price objective on Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a report on Tuesday, February 25th. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a research report on Tuesday. JMP Securities reiterated a "market outperform" rating and set a $33.00 price objective on shares of Artivion in a research report on Tuesday. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $32.00 price objective on shares of Artivion in a report on Tuesday. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Artivion currently has a consensus rating of "Buy" and a consensus price target of $31.40.

Artivion Stock Up 0.7 %

AORT traded up $0.20 on Friday, reaching $28.73. The company's stock had a trading volume of 87,202 shares, compared to its average volume of 314,880. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $32.33. The stock has a 50 day moving average of $24.09 and a two-hundred day moving average of $27.20. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -1,436.50 and a beta of 1.54.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $98.98 million for the quarter, compared to analyst estimates of $94.81 million. As a group, analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.